Anaptysbio (ANAB) Net Cash Flow (2016 - 2026)

Anaptysbio has reported Net Cash Flow for 11 years, with the latest figure at $10.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 142.03% year-over-year to $10.3 million; the trailing twelve-month figure through Mar 2026 stood at $149.8 million (up 233.39% YoY), and the FY2025 full-year result was $115.1 million, up 32.14% from the prior year.
• Net Cash Flow for Q1 2026 stood at $10.3 million, down from $128.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $128.4 million in Q4 2025, with the low at -$329.3 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$14.5 million across 5 years, with a median of $9.7 million in 2023.
• Annual changes were most pronounced in 2022 — Net Cash Flow slumped 1077.43% — and 2024, when it surged 1443.96%.
• Anaptysbio's Net Cash Flow stood at $12.8 million in 2022, then slipped by 24.22% to $9.7 million in 2023, then plunged by 808.39% to -$68.5 million in 2024, then soared by 287.39% to $128.4 million in 2025, then slumped by 92.0% to $10.3 million in 2026.
• The last three Net Cash Flow figures came in at $10.3 million (Q1 2026), $128.4 million (Q4 2025), and $65.5 million (Q3 2025), per Business Quant data.